CA2078700C - Imidazolylmethyl-pyridines - Google Patents
Imidazolylmethyl-pyridines Download PDFInfo
- Publication number
- CA2078700C CA2078700C CA002078700A CA2078700A CA2078700C CA 2078700 C CA2078700 C CA 2078700C CA 002078700 A CA002078700 A CA 002078700A CA 2078700 A CA2078700 A CA 2078700A CA 2078700 C CA2078700 C CA 2078700C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- acid addition
- addition salt
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- SQEUYNQLUMQWKJ-UHFFFAOYSA-N 2-(1h-imidazol-2-ylmethyl)pyridine Chemical class C=1C=CC=NC=1CC1=NC=CN1 SQEUYNQLUMQWKJ-UHFFFAOYSA-N 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 31
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 8
- 206010039966 Senile dementia Diseases 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 150000003839 salts Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 239000012458 free base Substances 0.000 claims description 8
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 3
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 3
- 201000010374 Down Syndrome Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- 206010020651 Hyperkinesia Diseases 0.000 claims description 3
- 208000000269 Hyperkinesis Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 3
- 206010044688 Trisomy 21 Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 206010028417 myasthenia gravis Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008024 pharmaceutical diluent Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- -1 imidazolylmethyl group Chemical group 0.000 claims 2
- 239000001530 fumaric acid Substances 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000000627 locus coeruleus Anatomy 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- LXBGSDVWAMZHDD-UHFFFAOYSA-N 2-methyl-1h-imidazole Chemical compound CC1=NC=CN1 LXBGSDVWAMZHDD-UHFFFAOYSA-N 0.000 description 1
- 241001363655 Jaton Species 0.000 description 1
- 238000011672 OFA rat Methods 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-M fumarate(1-) Chemical compound OC(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-M 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 210000004283 incisor Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000010413 mother solution Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Luminescent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4131584A DE4131584A1 (de) | 1991-09-23 | 1991-09-23 | Imidazolylmethyl-pyridine, ihre herstellung und anwendung als pharmazeutika |
| DEP4131584.7 | 1991-09-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2078700A1 CA2078700A1 (en) | 1993-03-24 |
| CA2078700C true CA2078700C (en) | 2005-09-13 |
Family
ID=6441240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002078700A Expired - Fee Related CA2078700C (en) | 1991-09-23 | 1992-09-21 | Imidazolylmethyl-pyridines |
Country Status (24)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217631A1 (en) * | 2017-05-22 | 2018-11-29 | Torrey Pines Institute For Molecular Studies | Compositions, methods of use, and methods of treatment |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10165349A (ja) * | 1996-12-06 | 1998-06-23 | Matsushita Electric Ind Co Ltd | 食器洗浄機 |
| DE10000161A1 (de) * | 2000-01-06 | 2001-07-19 | Boehringer Ingelheim Pharma | Verfahren zur Identifikation eines Proteaseinhibitors |
| GB0009037D0 (en) * | 2000-04-13 | 2000-05-31 | Novartis Ag | Organic compounds |
| BRPI0507859A (pt) * | 2004-02-19 | 2007-07-17 | Novartis Ag | uso dos inibidores da colinesterase |
| CA2616177C (en) | 2005-07-29 | 2012-05-01 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl-pyridines for the treatment of a sleep disorder |
| MX2008010322A (es) * | 2006-02-13 | 2009-03-05 | Vanda Pharmaceuticals Inc | Formulaciones de dosificacion estable de imidazolilalquil-piridina s. |
| WO2009097416A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl- pyridines as dbh inhibitors |
| JP6265583B2 (ja) | 2008-10-17 | 2018-01-24 | ウィスコンシン アルムニ リサーチ ファンデイション | 生理活性アルファベータペプチドを作製する方法 |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862340D1 (en) * | 1978-02-01 | 1983-11-24 | Wellcome Found | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof |
| GB2028317B (en) * | 1978-08-15 | 1982-11-10 | Pfizer Ltd | 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors |
| US4634711A (en) * | 1985-08-02 | 1987-01-06 | Smithkline Beckman Corporation | Pyridylalkyl imidazole-2-thiols |
| DE3811574A1 (de) * | 1988-03-31 | 1989-10-19 | Schering Ag | N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln |
-
1991
- 1991-09-23 DE DE4131584A patent/DE4131584A1/de not_active Withdrawn
-
1992
- 1992-09-09 HU HU9202886A patent/HUT61993A/hu unknown
- 1992-09-18 MY MYPI92001673A patent/MY110450A/en unknown
- 1992-09-21 FI FI924233A patent/FI103887B1/fi not_active IP Right Cessation
- 1992-09-21 DE DE59207425T patent/DE59207425D1/de not_active Expired - Lifetime
- 1992-09-21 EP EP92810719A patent/EP0534904B1/de not_active Expired - Lifetime
- 1992-09-21 CZ CS922896A patent/CZ281675B6/cs not_active IP Right Cessation
- 1992-09-21 NO NO923653A patent/NO301162B1/no not_active IP Right Cessation
- 1992-09-21 AT AT92810719T patent/ATE144509T1/de active
- 1992-09-21 SK SK2896-92A patent/SK289692A3/sk not_active IP Right Cessation
- 1992-09-21 IL IL10322992A patent/IL103229A/en not_active IP Right Cessation
- 1992-09-21 AU AU25226/92A patent/AU650569B2/en not_active Ceased
- 1992-09-21 NZ NZ244420A patent/NZ244420A/xx not_active IP Right Cessation
- 1992-09-21 DK DK92810719.2T patent/DK0534904T3/da active
- 1992-09-21 SG SG1996003366A patent/SG43079A1/en unknown
- 1992-09-21 CA CA002078700A patent/CA2078700C/en not_active Expired - Fee Related
- 1992-09-21 ES ES92810719T patent/ES2092666T3/es not_active Expired - Lifetime
- 1992-09-22 KR KR1019920017228A patent/KR100254085B1/ko not_active Expired - Fee Related
- 1992-09-22 MX MX9205365A patent/MX9205365A/es unknown
- 1992-09-22 RO RO92-01218A patent/RO109337B1/ro unknown
- 1992-09-22 RU SU925052552A patent/RU2058312C1/ru active
- 1992-09-22 JP JP4252692A patent/JP2568356B2/ja not_active Expired - Fee Related
- 1992-09-23 ZA ZA927279A patent/ZA927279B/xx unknown
- 1992-09-24 TW TW081107550A patent/TW222630B/zh active
-
1995
- 1995-06-13 HU HU95P/P00198P patent/HU211261A9/hu unknown
-
1996
- 1996-10-24 GR GR960402593T patent/GR3021444T3/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018217631A1 (en) * | 2017-05-22 | 2018-11-29 | Torrey Pines Institute For Molecular Studies | Compositions, methods of use, and methods of treatment |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI87785C (fi) | Foerfarande foer framstaellning av farmaceutiskt aktivt, kristallint paroxetinhydrokloridhemihydrat | |
| US4789678A (en) | Memory enhancing α-alkyl-4-amino-3-quinolinemethanols and 1-(4-aralkylamino-3-quinolinyl)alkanones and related compounds | |
| CA2078700C (en) | Imidazolylmethyl-pyridines | |
| WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
| CA3142069A1 (en) | Aurora kinase inhibitor and use thereof | |
| US6492407B2 (en) | Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones | |
| US6552018B1 (en) | Pyrazole derivatives | |
| KR900006742B1 (ko) | N-[(2-옥소피롤리딘-1-일)아세틸]피페라진 유도체 및 노인성 치매용 약제 | |
| DD286581A5 (de) | Verfahren zur herstellung von hetera-aliphatischem carbonsaeureamiden | |
| US20090197907A1 (en) | Novel crystalline form of rupatadine free base | |
| US5635521A (en) | Imidazolylmethyl-pyridines | |
| DE69702419T2 (de) | Substituierte Guanidin Derivate und ihre Verwendung als Na+/H+ Austausch Inhibitoren | |
| DE2748827A1 (de) | 3,3-dichlorazetidinonderivate und ihre verwendung | |
| DE1720033A1 (de) | Neue Indolderivate und Verfahren zu ihrer Herstellung | |
| HUP0204572A2 (en) | Substituierte bisindolylmaleinimide derivatives, process for their preparation and use and pharmaceutcial compositions containing them | |
| FI62056B (fi) | Foerfarande foer framstaellning av nya farmakologiskt verksamma substituerade nitrobenzofenonderivat | |
| DE68913167T2 (de) | Indol-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate. | |
| HU187600B (en) | Process for preparing 2-methyl-9,10-didehydro-ergolines | |
| CS240970B2 (en) | Process for preparating substituted phenylalkylamides ofphenylacetic acid | |
| EP0122376B1 (en) | Anticholinesterase pyridine derivatives | |
| DE2166019C3 (de) | 2-Substituierte 1 -Phenylcyclohex-3en-1-carbonsäureester und ihre Salze und Verfahren zu deren Herstellung | |
| KR790001982B1 (ko) | 1, 2, 3, 4-테트라하이드로벤조 이소퀴놀린류의 제조방법 | |
| JPH01104041A (ja) | Ｎ−［（２−オキソ−１−ピロリジニル）アセチル］ピペラジン誘導体、その製造方法および老人性痴呆症薬 | |
| JPS60136556A (ja) | ビスアミジンジフエニル誘導体およびそれらの製法 | |
| KR800001508B1 (ko) | 트리아졸릴페닐케톤 유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |